• 1. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 2. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 3. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 4. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 5. Aggregation kinetics and gel formation in modestly concentrated suspensions of oppositely charged model ceramic colloids: a numerical study
  M. A. Piechowiak,A. Videcoq,R. Ferrando,D. Bochicchio,C. Pagnoux,F. Rossignol Phys. Chem. Chem. Phys., 2012,14, 1431-1439

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams Imidolactams
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams

Professional Introduction to 1H-Pyrazol-3-amine, 1-(2-methoxypropyl) and CAS No. 1567095-72-0

The compound 1H-Pyrazol-3-amine, 1-(2-methoxypropyl), identified by the CAS number 1567095-72-0, represents a significant advancement in the field of pharmaceutical chemistry and medicinal research. This heterocyclic amine derivative has garnered considerable attention due to its unique structural properties and potential therapeutic applications. The pyrazole core, a six-membered aromatic ring containing two nitrogen atoms, is a privileged scaffold in drug discovery, known for its ability to interact with biological targets in diverse ways. The introduction of a 2-methoxypropyl side chain at the 1-position introduces steric and electronic modifications that can influence both the compound's solubility and its binding affinity to biological receptors.

Recent studies have highlighted the importance of pyrazole derivatives in the development of novel therapeutic agents. The amine functionality at the 3-position of the pyrazole ring provides a versatile handle for further chemical modifications, enabling the synthesis of a wide array of analogs with tailored pharmacological profiles. This compound, in particular, has been explored for its potential role in modulating enzyme activity and receptor interactions. For instance, researchers have investigated its interaction with Janus kinases (JAKs), a family of enzymes implicated in various inflammatory and autoimmune diseases. Preliminary computational studies suggest that the 1-(2-methoxypropyl) substitution may enhance binding affinity to JAK2 by optimizing the orientation of key hydrogen bonding interactions.

The 1H-Pyrazol-3-amine, 1-(2-methoxypropyl) structure also exhibits interesting physicochemical properties that make it an attractive candidate for drug development. The methoxypropyl group contributes to increased lipophilicity, which can improve membrane permeability and oral bioavailability—a critical factor in pharmaceutical design. Additionally, the presence of both nitrogen and oxygen atoms allows for multiple hydrogen bonding interactions with biological targets, enhancing binding stability. These characteristics have prompted investigations into its potential as an inhibitor of protein-protein interactions (PPIs), which are often implicated in cancer and other chronic diseases.

In the realm of medicinal chemistry, the synthesis of 1H-Pyrazol-3-amine, 1-(2-methoxypropyl) has been optimized using multi-step organic transformations. Key synthetic strategies include nucleophilic substitution reactions at the pyrazole ring followed by functional group interconversions to introduce the desired side chains. Advances in catalytic methods have further refined these processes, enabling higher yields and purities while minimizing waste. The compound's stability under various storage conditions has also been evaluated, ensuring its suitability for both laboratory research and potential clinical trials.

Emerging research indicates that derivatives of this compound may exhibit significant anti-inflammatory properties. Studies on related pyrazole amides have demonstrated their ability to inhibit inflammatory cytokine production by modulating signaling pathways such as NF-κB. The structural motif of 1H-Pyrazol-3-amine, 1-(2-methoxypropyl) suggests similar mechanisms may be operative, making it a promising candidate for treating conditions like rheumatoid arthritis or inflammatory bowel disease. Furthermore, its interaction with cytochrome P450 enzymes has been assessed to evaluate potential metabolic pathways and drug-drug interaction risks—a critical consideration in clinical development.

The pharmacokinetic profile of 1H-Pyrazol-3-amine, 1-(2-methoxypropyl) is another area of active investigation. In vivo studies using appropriate animal models have begun to elucidate its absorption, distribution, metabolism, and excretion (ADME) properties. Initial findings suggest moderate oral bioavailability coupled with rapid clearance via renal excretion. These data are being used to guide further optimization efforts aimed at improving pharmacokinetic properties while maintaining efficacy. Additionally, toxicological assessments have been conducted to evaluate acute and chronic safety profiles, ensuring that preclinical development can proceed with confidence.

The versatility of 1H-Pyrazol-3-amine, 1-(2-methoxypropyl) as a chemical scaffold has also inspired investigations into its role as a building block for more complex drug candidates. By appending additional functional groups or linking it to other heterocyclic structures, researchers aim to generate novel molecules with enhanced therapeutic specificity or reduced side effects. Collaborative efforts between academic institutions and pharmaceutical companies are now focused on translating these early findings into clinical candidates for unmet medical needs.

In conclusion,1H-Pyrazol-3-amine, 1-(2-methoxypropyl) (CAS No. 1567095-72-0) represents a compelling example of how structural innovation in heterocyclic chemistry can yield compounds with significant therapeutic potential. Its unique combination of physicochemical properties and biological activity makes it an attractive focus for ongoing research in medicinal chemistry. As our understanding of disease mechanisms continues to evolve, compounds like this one will play an increasingly important role in shaping the next generation of therapeutic interventions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)